ArticleInfection and drug resistance2026
Development and Validation of a Novel Predictive Model and Simplified Clinical Indicator for Mortality in Severe Fever with Thrombocytopenia Syndrome Patients.
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Severe fever with thrombocytopenia syndrome (SFTS) is a highly fatal infectious disease endemic in rural areas, underscoring the need for early prognostic risk stratification. Patients and Methods: This study aimed to develop and validate a prognostic model using readily available clinical indicators. We conducted a retrospective analysis of 260 SFTS patients (mortality rate 19.6%), integrating epidemiological characteristics, clinical symptoms and laboratory variables through a hybrid multi-model feature screening approach incorporating univariate Cox, LASSO, Random Forest, and XGBoost algorithms. Results: Four core risk factors for mortality were identified: age ≥ 56 years, platelet count ≤ 44 × 10 Conclusion: The developed model and AER index provide valuable tools for early identification of high-risk SFTS patients, facilitating improved clinical management and resource allocation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.